Dec 23, 2025 08:28AM BriaCell Therapeutics announces public offering of up to $25 million

Oct 21, 2025 07:31AM BriaCell partners with MSK accelerator for breast cancer therapy

Oct 14, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Briacell Therapeutics (BCTX)

Aug 27, 2025 06:36AM Briacell Therapeutics (BCTX) PT Raised to $40 at H.C. Wainwright

Aug 26, 2025 07:38AM BriaCell study validates Bria-OTS+ cancer therapy mechanism

Aug 25, 2025 07:31AM BriaCell receives $2 million NCI grant for prostate cancer therapy

Aug 21, 2025 12:08PM BriaCell sets August 25 as effective date for 1-for-10 share consolidation

Aug 13, 2025 07:30AM BriaCell joins MSK cancer therapeutics accelerator program

Jul 30, 2025 07:31AM BriaCell receives New Zealand patent for whole cell cancer technology

Jul 11, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Briacell Therapeutics (BCTX)

Jul 8, 2025 04:11PM BriaCell Therapeutics (BCTX) Files for 6.83M Share and Warrant Offering

Jul 8, 2025 07:32AM BriaCell reports 52% one-year survival rate in breast cancer trial

Jul 2, 2025 07:31AM BriaCell Therapeutics (BCTX) Highlights Additional Phase 3 Clinical Sites

Jun 24, 2025 07:38AM BriaCell Therapeutics (BCTX) Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

May 27, 2025 07:31AM BriaCell Therapeutics' (BCTX) Bria-OTS Phase 1/2 Study Clears Safety Evaluation

May 23, 2025 07:42AM BriaCell Therapeutics (BCTX) Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

Apr 24, 2025 07:32AM BriaCell Therapeutics (BCTX) Confirms 100% Resolution of Lung Metastasis with Bria-OTS

Apr 23, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Briacell Therapeutics (BCTX)

Apr 22, 2025 07:31AM BriaCell Therapeutics (BCTX) Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer

Apr 16, 2025 07:31AM BriaCell Therapeutics (BCTX) Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Mar 20, 2025 08:02AM BriaCell Therapeutics (BCTX) Reports Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study

Feb 13, 2025 04:55PM BriaCell (BCTX) regains Nasdaq compliance with bid price

Feb 4, 2025 06:39AM Briacell Therapeutics (BCTX) PT Raised to $32 at H.C. Wainwright

Feb 3, 2025 04:45PM BriaCell Therapeutics (BCTX) Announces Proposed Public Offering of Common Shares

Feb 3, 2025 07:31AM BriaCell Therapeutics (BCTX) Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS

Dec 11, 2024 04:05PM BriaCell Therapeutics (BCTX) Announces Proposed Share Offering

Dec 2, 2024 12:24PM H.C. Wainwright Reiterates Buy Rating on Briacell Therapeutics (BCTX)

Dec 2, 2024 07:50AM BriaCell Therapeutics (BCTX) Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer

Oct 15, 2024 07:51AM BriaCell Therapeutics (BCTX) Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Study

Oct 3, 2024 07:03AM H.C. Wainwright Reiterates Buy Rating on Briacell Therapeutics (BCTX)

Oct 1, 2024 02:05PM BriaCell Therapeutics (BCTX) Announces $5 Million Offering

Oct 1, 2024 07:55AM BriaCell Therapeutics (BCTX) Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor

Sep 19, 2024 06:41AM Briacell Therapeutics (BCTX) PT Lowered to $15 at H.C. Wainwright

Sep 12, 2024 07:51AM H.C. Wainwright Reiterates Buy Rating on Briacell Therapeutics (BCTX)

Sep 11, 2024 12:10PM BriaCell Therapeutics (BCTX) Announces $8.5 Million Offering of Common Shares, Warrants

Sep 10, 2024 07:51AM BriaCell Therapeutics (BCTX) Announces Positive Pre-IND Meeting with FDA for Bria-PROS+ for Prostate Cancer

Jul 18, 2024 07:57AM BriaCell Therapeutics (BCTX) Quadruples Progression Free Survival in Patient with “Eye-Bulging” Metastatic Breast Cancer